Lipodisq™ Styrene:Maleic Acid Copolymer 1:1 [SMA-100] Cat. No. #IAX-700-201

Name: Lipodisq™ Styrene:Maleic Acid Copolymer 1:1 [SMA-100] Cat. No. #IAX-700-201 - 100 mg, UK VAT
Brand: Innaxon
SKU: IAX-700-201-M100
Price: 140.00 GBP
Availability: InStock

• A nanoparticle (11-40nm) drug delivery system comprising a discoidal phospholipid bilayer membrane stabilised by a chaperone molecular annulus.

• LipodisqTM polymers are available as 4 defined structures (1:1, 2:1, 3:1 and 4:1 Styrene to Maleic Acid (SMA) rations) each individually operational within a selected pH range for optimal working conditions.

• Components are batch-tested for LipodisqTM formation using buffer systems available, which are tested for nano-formulated drug analysis by Dynamic Light Scattering (DLS). These buffer solutions are endotoxin-tested and sterile.

• LipodisqTM formation is highly efficient and nanodiscs show a good safety profile and are suitable for in vitro and in vivo (in experimental animals) investigations.

£140.00

Description Features Resources

Synonyms	Lipodisq™ Styrene:Maleic Anhydride Copolymer 1:1 (pre-hydrolyzed), [SMA-100], P(SMA) 1:1
Molecular Formula	C₁₂H₁₀O₄Na₂
Size	100mg
MW	Polymer MW average: M_W: 5,500 M_w: MW based on weight M_N: 2,100 M_N: MW based on number
CAS	26762-29-8
Purity	>98%
Solution pH	4.25+/-0.25 in 5% ddWater
Solubility	Soluble in water, and buffer solutions (pH 3.50-5.50) to allow the formulation of a proprietary, thermostable, aqueous lipid nanoparticle (Lipodisq^TM, Malvern Cosmeceutics Ltd., Malvern UK). Avoid the use of buffers with divalent ions such as Ca⁺⁺ or Mg⁺⁺ (>2mM) or pH <3.5 or >5.5, which can cause P(SMA precipitation or interfere with SMA-Lipid Particle formulation or stability.
Formulation with Phospholipids	Lipodisq^TM are nanosized lipid-based discoidal particles that can be manufactured with P(SMA) and lipids such as DMPC (1,2-Dimyristoyl-sn-glycero-3-phosphocholine) (14:0 PC) (DMPC: IAX-700-400) to incorporate hydrophobic, poorly water-soluble active compounds, such as peptides, lipids, lipoproteins, transmembrane proteins and glycolipids. Applications of Lipodisq^TM include functional and structural characterisation of the cargo and drug delivery with improved bioavailability, and biological half-life in vivo (PD/PK) or delivery of antigens preserved in their native conformation for immunization purposes.

Appearance	White powder
Handling	Keep dry. Avoid skin and eye contact.

Shipping	Ambient
Storage	2-8°C or 15-25°C
Stability	Upon receipt, store product at ambient temperature. Freezing is not recommended. In its unopened original vial, the product is stable for at least 36 months when stored at ambient temperature. Once the glass vial is opened, or solubilized in sterile, endotoxin-free ddWater (IAX-900-902) or for example in pH adjusted, diluted NaCl /acetate buffer (IAX-900-010) and aliquoted into sterile vials under sterile conditions, the SMA polymer solution (e.g. at 5%) remains stable for an additional one month when stored at 2-8°C and kept sterile.

Lipodisq^TM Technology

A nanoparticle (11-40nm) drug delivery system comprising a discoidal phospholipid bilayer membrane stabilised by a chaperone molecule annulus.
Internal properties of the phospholipid membrane support the disposition and stabilisation of drug molecule candidates and preserve the native conformation of membrane molecules.
The resulting encapsulated actives are rendered water-soluble and specialised for intra-cellular penetration/delivery via endosomal uptake mechanisms.
Lipodisq^TM solutions show a good safety profile and are suitable for in vitro and in vivo investigations.
For a customizable biodegradable Lipodisq^TM version with a higher concentration of actives or an alternative lipid option, contact Innaxon.

Innaxon as the supplier also welcomes BULK enquiries for this product.

Legal Claim
The Lipodisq^TM technology is covered by one or more of the following patents owned by Malvern Cosmeceutics Limited: AU2006253886, CA2611144, CN101184473B, EP1890675, GB2426703, IN261468, JP5142898, US8623414 and WO/2021/005340A1 pending.

The purchaser is licensed under those patents to use these assemblies for the purpose of research and development only but not for the purpose of delivery of agents for clinical use to humans or veterinary use to animals for therapeutic, diagnostic or prophylactic purposes, which uses are specifically prohibited.

Authorized Uses & Restrictions
The purchase of Innaxon product(s) conveys to the buyer the non-transferable right to use the purchased amount of the product and all replicates and derivatives for, internal, non-profit research purposes. The buyer cannot sell, resale or otherwise transfer (a) the product (b) its components or (c) materials made using this product or its components to a third party. The buyer agrees that any activity undertaken with the product and replicates or derivatives will be conducted in compliance with all applicable guidelines, aws, and regulations. The buyer agrees that the product and replicates or derivatives will not be used for any animal or human therapeutic or diagnostic use.

Limited Use License
Purchase does not include any other right or license to use, develop or otherwise exploit our products. Any use of Innaxon products outside of the Authorized Uses requires additional rights from the Licensor.

Download Product Resources

Product Data Sheet
Safety Data Sheet (available upon request)